• Home
  • EMCrit-RACC
  • PulmCrit
  • IBCC
  • EMNerd
  • Tox & Hound
  • About
    • About EMCrit
    • About PulmCrit
    • EMCrit FAQ
    • Subscription Options
  • Contact Us

PulmCrit (EMCrit)

Online Medical Education on Emergency Department (ED) Critical Care, Trauma, and Resuscitation

  • About PulmCrit
  • Genius General Hospital
  • PulmCrit TOC
  • IBCC TOC
  • IBCC Podcast
You are here: Home / Archives for PULMCrit

PulmCrit Wee – Follow-up Bamlanivimab study unmasks statistical chicanery

January 26, 2021 by Josh Farkas 1 Comment

Whether or not you have any interest in bamlanivimab, you should read this post as an amusing example of shoddy statistics being published in top journals.  background & general landscape of the two trials The BLAZE-1 trial involved randomizing patients within three days of testing positive for COVID-19 to one of four arms:  placebo, 700 […]

IBCC – Revamped COVID chapter focusing on ICU & stepdown management

January 25, 2021 by Josh Farkas 1 Comment

The COVID chapter has been updated, overhauled, and refocused on the management of the sickest COVID patients (those requiring admission to ICU or stepdown units).  The new chapter removes more basic information about COVID that we’re all probably familiar with at this point (but the original, larger chapter is still available here). The goal of […]

IBCC chapter – Disseminated Intravascular Coagulation (DIC)

January 18, 2021 by Josh Farkas 1 Comment

Disseminated Intravascular Coagulation (DIC) is like the ARDS of the hematological system.  It’s not really one disorder, but rather a collection of different disorders with some shared features.  The diagnosis and optimal treatment remain elusive. The IBCC chapter is located 👉 here. The podcast & comments are below. Follow us on iTunes  

PulmCrit- RCTs don’t justify using convalescent plasma or antibody cocktails

January 14, 2021 by Josh Farkas 2 Comments

Passive immunity refers to the infusion of antibodies (either polyclonal antibodies in the form of convalescent plasma, or engineered monoclonal antibodies).  The goal is to neutralize viral particles, reduce viral replication, and thereby improve clinical outcomes.  This is a promising theory, but it requires evidentiary support in the form of randomized controlled trials.  So far, […]

PulmCrit – Six RCTs to answer one question: what is the role of tocilizumab in COVID-19?

January 12, 2021 by Josh Farkas 4 Comments

The REMAP-CAP trial recently detected mortality benefit from tocilizumab in patients with COVID-19.  However, several other RCTs have failed to find substantial benefit from tocilizumab.  This begs the question:  Has REMAP-CAP discovered a uniquely beneficial way to use tocilizumab, or is this simply a statistical outlier?   evidence roundup:  RCTs on tocilizumab Let’s review the trials.  […]

  • 1
  • 2
  • 3
  • …
  • 80
  • Next Page »

Follow EMCrit Everywhere

Click for More Subscribe Options


Other Stuff

  • Have a great idea for the next podcast? Share it here!
  • Tough Questions. Maybe you have an answer!
  • When you're done listening to the podcast,
    check out these great sites.

Who We Are

We are the EMCrit Project, a team of independent medical bloggers and podcasters joined together by our common love of cutting-edge care, iconoclastic ramblings, and FOAM.

Like Us on Facebook

Like Us on Facebook

Subscribe by Email

EMCrit is a trademark of Metasin LLC. Copyright 2009-. This site represents our opinions only. See our full disclaimer, our privacy policy, commenting policy and here for credits and attribution.